StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report released on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The stock has a market capitalization of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45. The company’s 50 day simple moving average is $0.14.
About Nabriva Therapeutics
Further Reading
- Five stocks we like better than Nabriva Therapeutics
- What is the Hang Seng index?
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- The Role Economic Reports Play in a Successful Investment Strategy
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.